Genetesis Develop NonInvasive Heart Imaging Technology For Emergency Rooms

Genetesis Develop NonInvasive Heart Imaging Technology For Emergency Rooms

Chest pain accounts for millions of annual emergency room visits every year, making it one of the most common complaints. Patients present with a spectrum of signs and symptoms, and ultimately about 75% of the cases will be of non-cardiac origin. However, determining whether a patient’s chest pain is cardiac or not is a complex and inefficient process, requiring invasive and lengthy tests that ultimately decrease quality of care.

The Cincinnati-based startup Genetesis is determined to build smarter tools for the emergency department, and is developing the next-generation electrocardiogram (ECG), a noninvasive imaging tool to visualize the heart’s electric currents. The technology utilizes the body’s weak magnetic field to reconstruct and monitor the electrical current flowing around a beating heart. Using the proprietary software, the Genetesis CardioFlux Mapping System, the startup not only allow operators to perform magnetocardiographic scans, but create dynamic functional images and run powerful analysis tools that provide and assist clinicians in diagnosing diseases and plan treatment. The powerful biomagnetic imaging tool has zero radiation exposure, require no injection, emits less energy than a TV, and can accurately predict and characterize abnormalities that are consistently missed by ECG’s.

Screenshot from
The current chest pain triage process can last up to 36 hours, consisting of several invasive tests, including blood tests, use of drugs to artificially increase heart rate and injection of radioisotopes. Despite this, these tests often lead to incorrect diagnoses, missing serious heart diseases in patients who are sent home, increasing the financial strain on the health system. Genetesis has developed a technology that can change the standard of care in emergency departments around the world. Their innovative platform provide a clinical decision support tool for a broad spectrum of cardiovascular diseases, optimizing cost, getting patients in and out faster than before, while enhancing clinical outcomes.

For millions of people worldwide who every year turn up at emergency rooms with symptoms of cardiac diseases, or people who live with the risk of heart disease, this could be a game changer. It will provide a reliable and accurate diagnostic tool, increasing access to quality care. In addition, the technology can be expanded beyond the cardiac market, potentially including brain imaging, to solve major challenges in the emergency room.

Genetesis was founded in 2013 by CEO Peeyush Shrivastava and has since won multiple awards, including NVIDIA’s Inception competition and 43North. In November 2016, the startup closed a $1.2 million seed financing round, co-led by CincyTech and Mark Cuban’s Radical Investments, with participation from Loud Capital, Danmar Capital, Wilson Sonsini Investment Company, and private angels. Genetesis is in 2017 part of the Medtech Innovator Accelerator, and is working to launch additional clinical studies and seek regulatory clearance from the FDA.